Subepidermal blistering disorder in a 16-year-old female: case report
SPMC J Health Care Serv. 2018;4(1):8 ARK: http://n2t.net/ark:/76951/jhcs3a9dx4
1Department of Dermatology, Southern Philippines Medical Center, JP Laurel Ave, Davao City, Philippines
Correspondence Maria Vinna Nicodemus Crisostomo, email@example.com
Article editor Janice Natasha Ng, Amariz Zarate
Received 15 May 2017
Accepted 9 October 2018
Cite as Crisostomo MVN, Lacuesta-Gutierrez MPM. Subepidermal blistering disorder in a 16-year-old female: case report. SPMC J Health Care Serv. 2018;4(1):8. http://n2t.net/ark:/76951/jhcs3a9dx4
Subepidermal blistering disorders (SBD) are autoimmune disorders of the skin caused by the presence of autoantibodies to the structural components of the basement membrane.1
All dermatologic conditions under this group histopathologically manifest as blister formation beneath the epidermis. SBD include the pemphigoid disorders [e.g., pemphigoid gestationis, mucous membrane cicatricial pemphigoid, bullous pemphigoid (BP)], linear IgA bullous dermatosis 2
epidermolysis bullosa acquisita (EBA), and anti-p200 pemphigoid.1
These diseases share some clinical features, including the presence of pruritic, tense blisters, but their differentiation based on clinical presentation alone is difficult, hence the need for laboratory diagnostics such as direct immunofluorescence (DIF) and antibody testing.3
There are a number of therapeutic options, but steroids are the first-line treatment.4
Here, we report the case of a 16-year-old female who presented with vesicobullous skin lesions and was managed as having a subepidermal blistering disorder based on histopathologic and immunologic findings.
A 16-year-old female was admitted in our hospital with a six-week history of generalized, erythematous, pruritic, urticarial plaques, which gradually progressed to tense vesicles and bullae on the face, trunk, upper extremities, and inner aspects of the thighs. Two weeks prior to admission, the patient consulted a dermatologist who prescribed betamethasone dipropionate + mupirocin ointment twice daily application on the lesions and oral cetirizine 10 mg once a day for 2 weeks. There was no history of drug intake prior to the onset of the lesions. She had no weight loss, easy fatigability, hair loss, photosensitivity, oral ulcers, or joint pains accompanying or preceding the lesions. No other family or household members had the same condition. Past medical history was unremarkable. She received due vaccinations until she was 1 year old. Development was at par with age. She had her menarche at 12 years old. She denied any sexual contact.
Dermatologic physical examination revealed multiple erythematous urticarial plaques on the face, back, upper extremities and inner thighs. There were multiple, tense bullae containing serous fluid on the trunk, axillae, and extremities. The sizes of the bullae ranged from 1-3cm in diameter. (Figures 1). Eroded plaques with purulent discharge were also noted. There were no mucosal lesions. Scarring, Nikolsky sign, and milia formation on or around the lesions were all absent. The rest of the physical examination findings were unremarkable.
Multiple, erythematous, urticarial plaques and papules, and eroded plaques with purulent discharge on the right axillary area (A) and abdomen (B), topped with tense vesicles and bullae containing clear fluid.
The patient's complete blood counts showed leukocytosis (20.09 x 103/ml) and eosinophilia (different count: 20%). Erythrocyte sedimentation rate was normal. ANA and anti-dsDNA levels were negative. Chest x-ray findings were within normal limits. Pregnancy test was negative. Culture and sensitivity of wound discharge showed no growth of organisms after five days.
Histopathologic examination of a vesicle located on the volar aspect of the left forearm revealed a subepidermal split with neutrophilic infiltrates (Figure 2), consistent with SBD. We sent a sample of perilesional skin from the trunk for (DIF). Results showed linear deposits of IgG and C3 on the basement membrane zone, consistent with pemphigoid disorders or epidermolysis bullosa acquisita. (Figure 3). The patient's anti-BP180 IgG was elevated at 82.43 U/mL (normal value: ≤ 9 U/mL).
Histopathology of the skin showing basket-weave stratum corneum (A: green arrow) overlying an acanthotic epidermis, with focal intraepidermal collections of neutrophils (A: red arrow). A subepidermal split filled with neutrophils and red blood cells is also noted (A: yellow arrow). The dermis reveals superficial dermal edema, with moderately dense perivascular inflammatory infiltrates composed of neutrophils, lymphocytes and eosinophils (hematoxylin-eosin stain, A: x10 and B: x40).
Direct immunofluorescence of perilesional skin (x40) showing linear deposits of IgG and C3 at the basement membrane zone (red arrow).
Considering the clinical presentation of the patient, the DIF findings of linear deposits of IgG and C3 at the dermoepidermal junction, and the presence of autoantibodies against BP180, we managed the patient as having a subepidermal blistering disorder.
Therapeutic approaches and outcomes
Upon admission, we gave the patient intravenous clindamycin 300 mg every 6 hours and gentamicin 80 mg once a day, both for one week, to cover the infection. Topical steroids was continued while awaiting the final biopsy results. After establishing the diagnosis of SBD through DIF, we started the patient on prednisone 50 mg/day (1 mg/kg/day based on patient’s weight of 50 kg). After the third day of prednisone, the old lesions did not improve and new lesions appeared, so we increased the dose to 70 mg/day (1.4 mg/kg/day). After the dose increase, no new vesicles appeared, and the old lesions healed, leaving only hypopigmented patches. We discharged the patient two weeks after admission with instructions to return for follow-up consultations.
Starting on the third week of steroid use, we attempted to titrate down the patient’s prednisone. However, on the 9th week, when the prednisone dose was 20 mg/day, the patient developed cushingoid facies. We added azathioprine starting at 50 mg/day with the aim to down-titrate the steroid over the next few weeks. On the 16th week, when the prednisone dose was 10 mg/day, the cushingoid facies resolved but the patient developed new vesicles, so we increased the azathioprine dose to 75 mg/day. The patient did not return for follow-up for a year, but we came to know upon her return that, within the year, she eventually discontinued taking azathioprine, and intermittently took prednisone 10 mg whenever new vesicles would appear. She returned for follow-up because she developed new urticarial plaques and vesicles with generalized distribution. We restarted the patient on prednisone 10 mg and azathioprine 25 mg. When the vesicles started to diminish in number, we tapered the prednisone dose over 24 weeks and discontinued azathioprine on the 16th week. In the course of tapering the doses, there was one episode of appearance of new vesicles, which we were able to control by increasing the steroid dose to 25 mg and the azathioprine dose to 50 mg for 2 months. By the time we discontinued the prednisone, the patient’s urticarial plaques and vesicles disappeared, and no new lesions developed.
SBD are characterized by distinctive blister formation due to autoantibodies that target the structural components of the skin’s basement membrane.1
The presence of autoantibodies against collagen XVII (BP180), which is a transmembrane protein structural component of the dermoepidermal anchoring complex,2
clinically manifests as multiple tense blisters with sizes ranging from a few millimeters to 3 cm in diameter, as in our patient.
We narrowed down the diagnosis for our patient’s condition based on her clinical features and laboratory results. We ruled out pemphigoid gestationis since it is a pregnancy-associated autoimmune skin disorder, and we have established at the outset that our patient was not pregnant.5
We also ruled out cicatricial pemphigoid since the disorder presents with blisters on mucous membranes, which were not observed in our patient.6
Likewise, we ruled out linear IgA bullous dermatitis because its characteristic appearance of urticarial plaques and papules surrounded by “string-of-pearls” blisters was not present in our patient.7
We focused on BP and EBA, since both conditions have similar clinical, histologic, and routine immunohistologic features.8
Both BP and EBA have female predominance and adult age of onset.9 10
BP, which mostly affects the elderly with mean age of onset around 80 years, accounts for 80% of SBD.5 11
It is characterized by generalized formation of tense blisters and pruritus.3
EBA, on the other hand, is divided into two types: inflammatory and mechanobullous.12
The mechanobullous type is seen in 0.33% of the patients and is characterized by multiple blisters on trauma-prone areas, such as the extensor surfaces of the extremities, along with milia formation and scarring.13
The inflammatory type more closely resembles BP, as it is also characterized by pruritus and generalized vesiculobullous lesions that affect the trunk, extremities, and skin folds.12 13
For our patient’s diagnosis, the presence of linear deposits of IgG and C3 on the basement membrane zone on DIF and elevation of anti-BP180 point towards BP, but we also strongly consider the inflammatory type EBA because of its clinical similarities with BP.
In salt-split skin test. the skin biopsy specimen is incubated for 24-72 hours in 1 mol/L NaCl solution and then split at the level of the lamina lucida by teasing the epidermis from the dermis.14 15 16 17
This procedure differentiates EBA from BP by delineating the location where antibodies bind to in the split skin.18
In BP, the antibodies bind to the epidermal side of the split skin, while in EBA antibodies bind to the dermal side.19
However, this examination was not performed in our patient.
Patients with SBD are commonly treated with glucocorticoids and immunosuppressants.20
Antihistamines may also be given to symptomatically treat pruritus. We started our patient initially on steroids, which produced only minimal improvement of the lesions. When we increased the steroid dose, the lesions healed significantly, but when we eventually tapered the dose, the lesions recurred. When our patient developed cushingoid facies, which is a known adverse effect of long-term steroid use, we gave azathioprine and gradually reduced the steroid dose. This led to the complete resolution of the patient’s skin lesions and Cushingoid facies.
Cytotoxic drugs, commonly used as antineoplastic agents, are also known to suppress the immune system and have been noted to be effective in the treatment of autoimmune diseases.21
Cyclophosphamide, a cytotoxic chemotherapy drug, has been effectively used for BP.22 23
Methotrexate, in combination with oral or topical corticosteroids, was also reported to be effective in treating BP and EBA.20
Likewise, intravenous immunoglobulin has been used as treatment for bullous autoimmune diseases, especially EBA.24 25
Plasmapheresis, alone or in combination with cyclophosphamide or azathioprine, is also a viable treatment option, especially for patients who do not respond to conventional therapies.22
Immediate diagnosis and treatment ensure good prognosis for patients with SBD,26
but there is a high recurrence rate related to down-titration or discontinuation of steroids.27
Our patient presented clinically with the classic signs of SBD. Recognizing the severity of the disease, we immediately initiated an oral steroid regimen, which we later modified by adding azathioprine to minimize adverse effects of long-term steroid use. Our prompt diagnosis and use of a carefully titrated combination of immunosuppressive drugs proved to be effective in treating our patient.
We would like to thank Dr Jasmin Jamora from the Section of Dermatology in St Luke’s Medical Center for providing the immunofluorescence report and images for this case report.
Access and license
This is an Open Access article licensed under the Creative Commons
4.0 International License, which allows
others to share and adapt the work, provided that derivative works
bear appropriate citation to this original work and are not used for
commercial purposes. To view a copy of this license, visit
1. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunologic Research. 2018; 66(1):6-17.
2. Powell AM, Sakuma-Oyama Y, Oyama N, Black MM. Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. Clin Exp Dermatol. 2005 Nov; 30(6):682-7.
3. Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtch Arztebl. 2011 Jun; 108(23):399-405.
4. Marinovic B. First line therapy. Nederlands Tijdschrift Voor Dermatologie En Venereologie. 2013; 23(3).
5. Habif TP. Vesicular and bullous diseases. In: Habif TP. Clinical Dermatology: A color guide to diagnosis and therapy. 6th ed. New York: Elsevier; 2016.
6. Billings SD. Dermatoses. In: Goldblum JR, Lamps LW, McKenney KJ, Myers JL. Rosai and Ackerman’s surgical pathology. 11th ed. New York: Elsevier; 2018.
7. Cunliffe T. Linear IgA disease (syn. chronic bullous disease of childhood; linear IgA bullous dermatosis) [Internet]. Rickmansworth: Primary Care Dermatology Society; 2014 [cited 2018 August 30]. Available from: http://www.pcds.org.uk/clinical-guidance/linear-iga-disease-syn.-chronic-bullous-disease-of-childhood-linear-iga-bul. Accessed 2018 August 30.
8. Valeski JE, Kumar V, Beutner EH, Cartone C, Kasprzyk K. Differentiation of bullous pemphigoid from epidermolysis bullosa acquisita on frozen skin biopsies. Int J Dermatol. 1992 Jan;31(1):37-41.
9. Fernandes MD, Chiminazzo MD, Tebcherani AJ, Aoki V, Sanchez APG. Inflammatory epidermolysis bullosa acquisita: case report. An Bras Dermatol. 2009 Apr; 84( 2 ): 181-184.
10. Calonje E, Brenn T, Lazar A. Inherited and autoimmune subepidermal blistering diseases. In: Calonje E, Brenn T, Lazar A. McKee 's Pathology of the skin. 4th ed. New York: Elsevier; 2012.
11. Patterson JW. The vesiculobullous reaction pattern. In: Patterson JW. Weedon’s skin pathology. 4th ed. New York: Elsevier Limited; 2016.
12. Kim JH, Kim SC. Epidermolysis bullosa acquisita. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1204-13.
13. Ludwig RJ. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013; 2013:812029.
14. Mohan KH, Pai S, Rao R, Sripathi H, Prabhu S. Techniques of immunofluorescence and their significance. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):415-9.
15. Celik G, Atay S. Acquired epidermolysis bullosa and linear immunoglobulin a bullous dermatosis. In: Gonul M, Cakmak S, editors. Autoimmune bullous diseases. IntechOpen; 2018 May 9.
16. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE. Differentiating Anti-Lamina Lucida and Anti-Sublamina Densa antibmz Antibodies by Indirect Immunofluorescence on 1.0 M Sodium Chloride-Separated Skin. J Investig Dermatol. 1984; 82:139-144.
17. De A, Rao R, Balachandran C. Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders. Indian J Dermatol. 2010; 55(4):334-6.
18. Mohan KH, Pai S, Rao R, Sripathi H, Prabhu S. Techniques of immunofluorescence and their significance. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):415-9.
19. Euroimmun. Autoimmune bullous dermatoses. [cited 2018 Jul 24]. Available from: https://www.euroimmun.com/documents/Indications/Autoimmunity/Dermatology/Desmoglein/EA_1490_I_UK_A.pdf
20. Han A. A practical approach to treating autoimmune bullous disorders with systemic medications. J Clin Aesthet Dermatol. 2009 May; 2(5):19-28.
21. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann Intern Med. 1998 Jun 15;128(12 Pt 1):1021-8.
22. Culton DA, Diaz LA. Treatment of subepidermal immunobullous diseases. Clin Dermatol. 2012 Jan-Feb; 30(1):95-102.
23. Mutasim DF. Therapy of autoimmune bullous diseases. Ther Clin Risk Manag. 2007 Mar; 3(1):29-40.
24. Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol. 2004;5(3):153-60.
25. Mehren CR, Gniadecki R. Epidermolysis bullosa acquisita: current diagnosis and therapy. Dermatol Reports. 2011 Oct 5; 3(3):e38.
26. Velez AMA, Vasquez-Hincapie DA, Howard MS. Autoimmune basement membrane and subepidermal blistering diseases. Our Dermatol Online. 2013; 4(Suppl. 3):647-662.
27. Tan SK, Tay YK. Bullous pemphigoid: Profile and outcome in a series of 100 cases in Singapore. J Dermatol Dermatol Surg 2018;22:12-5.
Copyright © 2018 MVN Crisostomo, et al.